Dean, Bonnie B.
Saundankar, Vishal
Stafkey-Mailey, Dana
Anguiano, Rebekah H.
Nelsen, Andrew C.
Gordon, Kathryn
Classi, Peter
Funding for this research was provided by:
United Therapeutics Corporation (Funding to Xcenda, LLC)
Article History
First Online: 6 March 2020
Change Date: 5 June 2020
Change Type: Correction
Change Details: Changes within text are indicated in <Emphasis Type="Bold">bold.</Emphasis>
Compliance with Ethical Standards
:
: This research was funded by United Therapeutics Corporation.
: Dr. Dean, Mr. Saundankar, and Dr. Stafkey-Mailey are employees of Xcenda, LLC, which received financial support for the conduct of this study. Dr. Anguiano has received personal fees from United Therapeutics Corporation, outside the submitted work. Dr. Nelsen, Dr. Gordon, and Mr. Classi are employees of United Therapeutics Corporation, manufacturer of oral treprostinil.
: The data that support the findings of this study are available from IBM<sup>®</sup>, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. However, data are available from the authors upon reasonable request and with permission of IBM<sup>®</sup>.